Monopar Therapeutics Inc. (MNPR) Stock

Monopar Therapeutics Inc. (MNPR) is a Healthcare stock trading at $108.03 (as of 2026-08-21), with a market capitalization of $725.08M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cancer-related treatments in the United States. Its pipeline includes Validive for preventing severe oral mucositis in oropharyngeal cancer, Camsirubicin for advanced soft tissue sarcoma, and MNPR-101 and related radioimmunotherapies for other cancer and severe COVID-19 indications.

Understand Monopar Therapeutics Inc.: how it makes money

Monopar Therapeutics develops cancer therapeutics in clinical trials, including Validive, a clonidine hydrochloride mucobuccal tablet in a Phase 2b/3 program to prevent severe oral mucositis from chemoradiotherapy in oropharyngeal cancer, plus Camsirubicin in Phase 1b for advanced soft tissue sarcoma and MNPR-101 for further cancer-related development.

Because it is a clinical-stage biopharmaceutical company with lead candidates in Phase 2b/3 and Phase 1b, its profit model hinges on trial progress and clinical outcomes, not on selling an established product revenue stream.

Business quality (Weak): Clear oncology focus and multiple clinical-stage assets, but the near-term business model remains dependent on clinical development outcomes and continued funding, with no reported revenue in the latest quarter.

Bull case

Lead program in late-stage development: Validive is in a Phase 2b/3 clinical trial for prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Encouraging trial signals in neurologic outcomes (within the provided metrics): The provided metrics show lower clinically meaningful neurologic worsening with Tiomolibdate Choline (9%) versus Standard of Care (25%), and higher clinically meaningful neurologic improvement with Tiomolibdate Choline (45%) versus Standard of Care (32%).
Additional oncology assets in the clinic: Camsirubicin is in Phase 1b for advanced soft tissue sarcoma, and MNPR-101 is also in development.

Bear case

No reported revenue in the latest period: Revenue is reported as 0.0B for the period ended 2025-09-30, which means economics depend on development progress rather than product sales.
Large operating losses: Operating margin is reported at -624.4 for the period ended 2025-09-30.
Clinical and safety uncertainty remains: The provided metric for drug-related serious adverse events is 4.9% of patients, and all stated programs are still in clinical trial stages.

Valuation — source: SEC EDGAR (first-party)
Price	$108.03
Market Cap	$725.08M
Price / Book	5.54
Price / Sales	370.95

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00

Financial Health — source: SEC EDGAR
Altman Z-Score	149.97 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Jupiter Topco LLC ($121.70M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Chandler D. Robinson
Employees	14
Country	US
IPO Date	2019-12-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.